These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Jean GW; Shah SR Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies in human cancer. Mellstedt H Drugs Today (Barc); 2003; 39 Suppl C():1-16. PubMed ID: 14988743 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies in the management of solid tumors. Kalofonos HP; Grivas PD Curr Top Med Chem; 2006; 6(16):1687-705. PubMed ID: 17017951 [TBL] [Abstract][Full Text] [Related]
7. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140 [TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. You B; Chen EX J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163 [TBL] [Abstract][Full Text] [Related]
10. New monoclonal antibodies in renal transplantation. Vincenti F Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967 [TBL] [Abstract][Full Text] [Related]
11. [The Brazilian market for monoclonal antibodies used in cancer treatment]. Vidal TJ; Figueiredo TA; Pepe VLE Cad Saude Publica; 2018 Nov; 34(12):e00010918. PubMed ID: 30517310 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic antibodies against cancer. Adler MJ; Dimitrov DS Hematol Oncol Clin North Am; 2012 Jun; 26(3):447-81, vii. PubMed ID: 22520975 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor monoclonal antibodies in conjunction with β-glucans: a novel anti-cancer immunotherapy. Xiang D; Sharma VR; Freter CE; Yan J Curr Med Chem; 2012; 19(25):4298-305. PubMed ID: 22834812 [TBL] [Abstract][Full Text] [Related]
14. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803 [TBL] [Abstract][Full Text] [Related]
15. Overview of monoclonal antibodies in cancer therapy: present and promise. Stern M; Herrmann R Crit Rev Oncol Hematol; 2005 Apr; 54(1):11-29. PubMed ID: 15780905 [TBL] [Abstract][Full Text] [Related]
16. Development of antibodies and chimeric molecules for cancer immunotherapy. Waldmann TA; Morris JC Adv Immunol; 2006; 90():83-131. PubMed ID: 16730262 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies as therapeutic agents for cancer. Harris M Lancet Oncol; 2004 May; 5(5):292-302. PubMed ID: 15120666 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic monoclonal antibodies: trends in development and approval in the US. Reichert JM Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031 [TBL] [Abstract][Full Text] [Related]